Lithuania Pharmaceuticals and Healthcare Report Q3 2007
Business Monitor International, October 2007, Pages: 58
The Lithuania Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Lithuania's pharmaceuticals and healthcare industry.
The total Lithuanian pharmaceutical market grew by 14% year-on-year (y-o-y) for the three months February through April 2007, according to distributor Tamro. This is up on the y-o-y growth rate of 9% in 2006, which saw the market reach a total value of US$447mn. The author maintains its forecast, which sees the average five-year annual growth rate between 2006 and 2011 at 6.5%, with total market value reaching US$612mn at the end of the period. However, the figures are contingent on the country’s fractious parliament and current weak government managing to steward the fast-growing economy or fresh elections yielding more workable arrangements before the next round of scheduled parliament polls in October 2008.
In the meantime, the country’s creaking public services – in particular healthcare – require urgent attention despite the attempts of successive governments to develop a modern primary sector, with doctors providing a gatekeeper function to specialists. While the president appears committed to reducing corruption, power struggles and appeals to populism are blamed for preventing movement on badly needed economic and social reforms. Nevertheless, the new multiparty governing coalition has put forward a platform based on investment in social services, although the fractious political scene threatens to derail the much-needed reforms.
In the adjusted Business Environment Rankings for the 15 major markets of Central & Eastern Europe (CEE), Lithuania again ranks joint tenth, this time on a par with Latvia and Slovakia. The country’s position has not changed, mostly due to relative improvements in other markets. While Lithuania’s strong economic growth and surging levels of consumer spending are stimulating pharmaceutical market growth, economic and political risks remain a cause for concern. Lithuania is expected to fully harmonise national with EU pharmaceutical legislation by the end of 2007, which should further facilitate market entry for foreign players.
In the meantime, having consolidated in the run-up to European Union (EU) membership, the country’s drug manufacturing sector will remain small and export-oriented, with even larger players potentially emerging as take-over targets in the medium to longer term. Multinationals will continue to supply the bulk of branded medicines through imports, although no plans are being made for establishing local manufacturing facilities. The strong local demand for generics is fuelling the expansion of large CEE players in the Lithuanian market.
Executive Summary
Lithuania Pharmaceuticals & Healthcare Industry SWOT
Political SWOT
Economic SWOT
Business Environment SWOT
Business Environment Ranking
Table: Business Environment Ranking – Central Eastern Europe
Business Environment Ranking
Economics – Long-Term Risk
Politics – Long-Term Risk
Regulatory Barriers
Domestic Sector Threat
Market Growth Potential
Market Size Ranking
Market Summary
Regulatory Regime
Recent Regulatory Developments
Intellectual Property Developments
USTR "Special 301" Report
Pricing Regime
Reimbursement Regime
Industry Developments
Health Profile
Healthcare System
Healthcare Funding
Healthcare Insurance
Corruption
Pharmaceutical Industry
Drugmakers Distributors And Retailers Active In The Baltic States During Q207
Recent Pharmaceutical Industry Developments
Wholesale
Retail
Biotechnology
Industry Forecast Scenario
Overall Market Forecast
Table: Lithuania Drug Market Forecast Indicators
Key Growth Factors – Industry
Table: Lithuania Healthcare Expenditure Forecast Indicators
Key Growth Factors – Macroeconomic
Table: Lithuania - Economic Activity
Prescription Market Forecast
Table: Lithuania Prescription Drug Market Forecast Indicators
OTC Market Forecast
Table: Lithuania OTC Market Forecast Indicators
Generics and Branded Market Forecast
Table: Lithuania Generics and Branded Market Forecast Indicators
Export/Import Forecasts
Table: Lithuania Pharmaceutical Export & Import Forecast Indicators
Other Healthcare Data Forecasts
Table: Other Healthcare Data Forecasts
Key Risks To Our Forecast Scenario
Competitive Landscape
Company Monitor
Indigenous Company Profiles
Valentis
Sanitas
Multinational Company Profiles
GlaxoSmithKline
Pfizer
Novartis
Sanofi-Aventis
Merck & Co
Our Forecast Modelling
How We Generate Our Industry Forecasts
Technical Process
Pharmaceutical Industry
Sources
- GlaxoSmithKline
- Merck & Co
- Novartis
- Pfizer
- Sanitas
- Sanofi-Aventis
- Valentis
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
